Hemolytic uremic syndrome in children.

Area of Science:

• Nephrology
• Hematology
• Immunology

Background:

• Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by thrombocytopenia, hemolytic anemia, and acute kidney injury.
• HUS is broadly classified into Shiga toxin-producing E. coli (STEC)-HUS (D+HUS) and atypical HUS (aHUS, D-HUS), with emerging recognition of HUS in systemic diseases.
• The complement system plays a crucial role in both typical and atypical HUS, with infections potentially unmasking underlying complement dysregulation.

Purpose of the Study:

• To review the classification, clinical manifestations, and pathogenic mechanisms of different HUS subtypes.
• To discuss current and emerging therapeutic strategies for STEC-HUS and atypical HUS.
• To highlight the importance of early diagnosis and personalized treatment approaches.

Main Methods:

• Review of existing literature on HUS classification, pathogenesis, and treatment.
• Analysis of clinical presentations distinguishing STEC-HUS from atypical HUS.
• Evaluation of the efficacy of supportive care and novel therapies, including eculizumab.

Main Results:

• STEC-HUS typically presents as an acute event following infection, while atypical HUS is often a chronic condition with poorer prognosis.
• Clinical symptoms can overlap across HUS types, necessitating precise etiological diagnosis.
• Eculizumab, a C5 complement inhibitor, has demonstrated significant improvements in hematological parameters and renal function in atypical HUS patients.

Conclusions:

• Understanding the diverse etiologies and pathogenic mechanisms of HUS is critical for effective management.
• Supportive care remains essential for STEC-HUS, while targeted therapies like eculizumab offer new hope for atypical HUS.
• Renal transplantation with prophylactic eculizumab may be considered for patients with end-stage renal disease due to recurrent atypical HUS.